Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

109.40 -0.87 (-0.79%)
Official Closing Price Updated: 7:00 PM EDT, Oct 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,006,724
Open 110.70
Bid (Size) 109.09 (1)
Ask (Size) 109.39 (1)
Prev. Close 110.27
Today's Range 109.17 - 110.83
52wk Range 99.14 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 2.67%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker'
Goldman Sachs identifies 18 stocks for potential earnings upside and advises options-based strategies in a volatile market. 10% upside for S&P 500. 
Via Benzinga
Topics Stocks
Exposures US Equities
Personalized Treatment And Immunotherapy Are Pharma's Newest Weapons Against Cancer
On Sunday, The Guardian issued an article that spoke of a UK study that could transform how cancer is treated. The large-scale clinical project assessed how personalized cancer therapies could... 
Via Benzinga

Performance

YTD
-3.39%
-3.39%
1 Month
-5.14%
-5.14%
3 Month
-15.17%
-15.17%
6 Month
-13.28%
-13.28%
1 Year
+5.74%
+5.74%

More News

Read More
NYSE:MRK stands out as a stock that provides good value for the fundamentals it showcases.
Via Chartmill
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock'
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Demystifying Merck & Co: Insights From 8 Analyst Reviews
Via Benzinga
Exploring The Competitive Space: Merck & Co Versus Industry Peers In Pharmaceuticals
Via Benzinga
New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and Portfolio
From Merck & Co., Inc.
Via Business Wire
Merck's Mumps Vaccine Controversy: Class-Action Lawsuit Alleges Anticompetitive Behavior, Court Shields From Liability
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Merck Touts Phase 3 Success For $20B Cancer Drug Keytruda In Untreated Head And Neck Cancer Patients
Via Benzinga
Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Event-Free Survival (EFS) as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced Head and Neck Squamous Cell Carcinoma
From Merck & Co., Inc.
Via Business Wire
Is Merck Stock a Buy?
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts
Via The Motley Fool
Is It Time to Buy September's Worst-Performing Dow Jones Stocks?
Via The Motley Fool
Topics Stocks
Exposures US Equities
3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
Via Benzinga
Exposures Product Safety
Could Summit Therapeutics Become the Next Merck?
Via The Motley Fool
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
Via Investor Brand Network
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
Via FinancialNewsMedia
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
The Covid Era Tech Promises To Reinvent Cancer Treatment
Via Benzinga
Exposures COVID-19
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit
Via News Direct
Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
From Merck & Co., Inc.
Via Business Wire
Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31
From Merck & Co., Inc.
Via Business Wire
2 High-Potential Growth Stocks You Shouldn't Overlook
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.